Sutro Biopharma develops protein therapeutics by using OCFS protein synthesis technology.
Industries BiotechnologyInformation TechnologyMedicalHeadquarters Regions San Francisco Bay Area, West Coast, Western US Founded Date 2003 Founders James R. Swartz Operating Status Active Last Funding Type Post-IPO Debt Also Known As Fundamental Applied Biology Legal Name Sutro Biopharma, Inc.
Stock Symbol NASDAQ:STRO Company Type For Profit
Contact Email general@sutrobio.com Phone Number 650-392-8412
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF.
Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.